Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06196879 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
A Phase 2 study of Severe Asthma, sponsored by Upstream Bio.
- Active
- Registry status
- Phase 2
- Development phase
- 479
- Enrollment target
- 20
- Study locations
NCT06196879: Active Phase 2 study of Severe Asthma, sponsored by Upstream Bio.
NCT06196879 is a Phase 2 study of Severe Asthma that is active but no longer recruiting, run by Upstream Bio. The registered enrollment target is 479 participants, below the 3,802-participant average among 9 other Severe Asthma trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06196879, a Phase 2 study of Severe Asthma, is active but no longer recruiting, sponsored by Upstream Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 479 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Primary Outcome
An asthma exacerbation is defined as a worsening of asthma that required treatment with systemic (oral or intravenous) corticosteroids for at least three consecutive days or a single depo-injectable dose of corticosteroids or an emergency room (ER) or urgent care visit that required systemic corticosteroids or an admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for greater than or equal to 24 hours.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Verekitug (UPB-101)
Study Locations (20)
Florida
- Advance Pharma Research - Cutler Bay
- Unique Clinical Trials - Doral
- Health and Life Research Institute, LLC - Miami
- Phoenix Medical Research - Miami
- Research Institute of South Florida - Miami
- Nouvelle Clinical Research - Miami
- Anderson Allergy And Asthma, PA - Orlando
- Edward Jenner Research Group, LLC - Plantation
- R&B Medical Center - Tampa
- Clinical Site Partners dba Flourish research - Winter Park
California
- Kern Research, Inc. - Bakersfield
- Velocity Clinical Research - Lafayette LA - Los Angeles
- Newport Native MD Inc - Newport Beach
- California Medical Research Associates Inc. - Northridge
- Integrated Research of Inland Inc - Upland
- Allergy & Asthma Clinical Research - Walnut Creek
- Allianz Research Institute - Westminster
- Woodland Clinic Medical Group - Woodland
Alabama
- AllerVie Clinical Research - Birmingham
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2024-02-27 |
| Est. Completion | 2026-06-11 |
| Phase | Phase 2 |
What the registry record for NCT06196879 still lists
NCT06196879 is an interventional study that assigns participants to a tested intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap, below the 3,802-participant average among 9 other Severe Asthma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06196879 names 20 study sites across 4 states, led by Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06196879 about?
NCT06196879 is a clinical study titled "A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)". The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability o...
What is the current status of trial NCT06196879?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2024-02-27. Estimated completion is 2026-06-11.
What conditions does trial NCT06196879 study?
This clinical trial studies the following conditions: Severe Asthma.
What interventions are being tested in trial NCT06196879?
The interventions under investigation include: Placebo (DRUG), Verekitug (UPB-101) (DRUG).
Who is sponsoring clinical trial NCT06196879?
This trial is sponsored by Upstream Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06196879 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06196879's enrollment target sits among peer trials
479 4th of 9 higher than 6 of 9 other Severe Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
RECRUITING · Phase 2
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
RECRUITING · Phase 3
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI